Research graph
References from A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol. Local targets link to admitted publications; unresolved targets remain external evidence.
Global colorectal cancer burden in 2020 and projections to 2040
10.1016/j.tranon.2021.101174 · 2021 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Unresolved reference
External reference
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
2019 · External reference
Colorectal Cancer: Management of Distant Metastases.
10.1007/978-3-030-66049-9_31 · 2022 · External reference
The immune contexture in cancer prognosis and treatment
10.1038/nrclinonc.2017.101 · 2017 · External reference
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
10.1126/science.1129139 · 2006 · External reference
The consensus molecular subtypes of colorectal cancer
10.1038/nm.3967 · 2015 · External reference
Biomarker-guided therapy for colorectal cancer: strength in complexity
10.1038/s41571-019-0241-1 · 2020 · External reference
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
10.1182/blood-2011-10-384388 · 2012 · External reference
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
10.1200/jco.2014.56.2025 · 2015 · External reference
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
10.1016/s0140-6736(14)61403-3 · 2015 · External reference
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
10.1038/s41591-024-03109-0 · 2024 · External reference
Cancer regression in patients after transfer of genetically engineered lymphocytes
10.1126/science.1129003 · 2006 · External reference
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
10.1200/jco.2010.32.2537 · 2011 · External reference
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
10.1136/jitc-2022-005755 · 2022 · External reference
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
10.1056/nejmoa2210233 · 2022 · External reference
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
10.1002/mc.23193 · 2020 · External reference
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
10.1097/00002371-200205000-00007 · 2002 · External reference
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
10.1200/jco.2016.66.7220 · 2016 · External reference
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
10.1158/1078-0432.ccr-11-0116 · 2011 · External reference
Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer
10.1038/sj.bjc.6603126 · 2006 · External reference
Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer
10.1245/s10434-010-0920-8 · 2010 · External reference
Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer
10.1007/s00262-015-1715-3 · 2015 · External reference
Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer
10.3109/21681805.2015.1059880 · 2015 · External reference
Unresolved reference
External reference
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
10.1200/jco-25-00765 · 2025 · External reference
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
10.1038/s41591-025-03627-5 · 2025 · External reference
Neoantigens in cancer immunotherapy
10.1126/science.aaa4971 · 2015 · External reference
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
10.1016/bs.ai.2016.01.001 · 2016 · External reference
Sensitive detection of antigen-specific T-cells using bead-bound antigen for in vitro re-stimulation
10.1016/j.mex.2019.07.004 · 2019 · External reference
Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor gamma-chain signaling
10.1182/blood.v97.1.205 · 2001 · External reference
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles
10.1111/j.1365-2567.2005.02268.x · 2006 · External reference
Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response
10.1016/j.celrep.2015.04.009 · 2015 · External reference
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
10.1016/s0140-6736(21)00933-8 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The Concept of the Sentinel Lymph Node
10.1007/978-3-642-57151-0_9 · 2000 · External reference
Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy
10.1136/jitc-2023-008026 · 2024 · External reference
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
10.1200/jco.2008.16.5449 · 2008 · External reference
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
10.1182/blood.v96.8.2712 · 2000 · External reference
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
10.1182/blood.v100.2.397 · 2002 · External reference
Managing the toxicities of CAR T-cell therapy
10.1002/hon.2595 · 2019 · External reference
Surgical complications in colorectal cancer patients
10.1016/j.amsu.2020.04.024 · 2020 · External reference
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
10.1136/jitc-2023-006822 · 2024 · External reference
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
10.1136/jitc-2021-003499 · 2021 · External reference
Unresolved reference
External reference
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
10.1056/nejmoa1500596 · 2015 · External reference
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
10.1038/s41591-020-0805-8 · 2020 · External reference
Nonoperative Management of Mismatch Repair-Deficient Tumors
10.1056/nejmoa2404512 · 2025 · External reference
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer
10.1158/0008-5472.can-10-2907 · 2011 · External reference
Managing the toxicities of CAR T-cell therapy
10.1002/hon.2595 · ExternalCitation · doi-reference
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
10.1002/mc.23193 · ExternalCitation · doi-reference
Colorectal Cancer: Management of Distant Metastases.
10.1007/978-3-030-66049-9_31 · ExternalCitation · doi-reference
The Concept of the Sentinel Lymph Node
10.1007/978-3-642-57151-0_9 · ExternalCitation · doi-reference
Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer
10.1007/s00262-015-1715-3 · ExternalCitation · doi-reference
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
10.1016/bs.ai.2016.01.001 · ExternalCitation · doi-reference
Surgical complications in colorectal cancer patients
10.1016/j.amsu.2020.04.024 · ExternalCitation · doi-reference
Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response
10.1016/j.celrep.2015.04.009 · ExternalCitation · doi-reference
Sensitive detection of antigen-specific T-cells using bead-bound antigen for in vitro re-stimulation
10.1016/j.mex.2019.07.004 · ExternalCitation · doi-reference
Global colorectal cancer burden in 2020 and projections to 2040
10.1016/j.tranon.2021.101174 · ExternalCitation · doi-reference
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
10.1016/s0140-6736(14)61403-3 · ExternalCitation · doi-reference
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
10.1016/s0140-6736(21)00933-8 · ExternalCitation · doi-reference
The consensus molecular subtypes of colorectal cancer
10.1038/nm.3967 · ExternalCitation · doi-reference
The immune contexture in cancer prognosis and treatment
10.1038/nrclinonc.2017.101 · ExternalCitation · doi-reference
Biomarker-guided therapy for colorectal cancer: strength in complexity
10.1038/s41571-019-0241-1 · ExternalCitation · doi-reference
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
10.1038/s41591-020-0805-8 · ExternalCitation · doi-reference
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
10.1038/s41591-024-03109-0 · ExternalCitation · doi-reference
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
10.1038/s41591-025-03627-5 · ExternalCitation · doi-reference
Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer
10.1038/sj.bjc.6603126 · ExternalCitation · doi-reference
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
10.1056/nejmoa1500596 · ExternalCitation · doi-reference
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
10.1056/nejmoa2210233 · ExternalCitation · doi-reference
Nonoperative Management of Mismatch Repair-Deficient Tumors
10.1056/nejmoa2404512 · ExternalCitation · doi-reference
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
10.1097/00002371-200205000-00007 · ExternalCitation · doi-reference
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles
10.1111/j.1365-2567.2005.02268.x · ExternalCitation · doi-reference
Cancer regression in patients after transfer of genetically engineered lymphocytes
10.1126/science.1129003 · ExternalCitation · doi-reference
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
10.1126/science.1129139 · ExternalCitation · doi-reference
Neoantigens in cancer immunotherapy
10.1126/science.aaa4971 · ExternalCitation · doi-reference
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
10.1136/jitc-2021-003499 · ExternalCitation · doi-reference
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
10.1136/jitc-2022-005755 · ExternalCitation · doi-reference
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
10.1136/jitc-2023-006822 · ExternalCitation · doi-reference
Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy
10.1136/jitc-2023-008026 · ExternalCitation · doi-reference
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer
10.1158/0008-5472.can-10-2907 · ExternalCitation · doi-reference
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
10.1158/1078-0432.ccr-11-0116 · ExternalCitation · doi-reference
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
10.1182/blood-2011-10-384388 · ExternalCitation · doi-reference
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
10.1182/blood.v100.2.397 · ExternalCitation · doi-reference
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
10.1182/blood.v96.8.2712 · ExternalCitation · doi-reference
Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor gamma-chain signaling
10.1182/blood.v97.1.205 · ExternalCitation · doi-reference
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
10.1200/jco-25-00765 · ExternalCitation · doi-reference
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
10.1200/jco.2008.16.5449 · ExternalCitation · doi-reference
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
10.1200/jco.2010.32.2537 · ExternalCitation · doi-reference
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
10.1200/jco.2014.56.2025 · ExternalCitation · doi-reference
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
10.1200/jco.2016.66.7220 · ExternalCitation · doi-reference
Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer
10.1245/s10434-010-0920-8 · ExternalCitation · doi-reference
Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer
10.3109/21681805.2015.1059880 · ExternalCitation · doi-reference
